ReviewInternational journal of molecular sciences2021
Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Is Palivizumabe a Protective Factor for the Development of Asthma in Children? A Systematic Review With Metanalysis.Pediatric pulmonology · 2025Pooled it
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Screening of key host targets and mechanistic assessment of berberine modulation of host responses to respiratory syncytial virus.The Journal of international medical research · 2026Article
- Real-World Effectiveness of Universal Nirsevimab on Bronchiolitis Incidence: A Regional Hub-Spoke Surveillance Analysis in Liguria, Italy.Pediatric pulmonology · 2026Article
- The dual threat: exploring the emergence of human metapneumovirus and SARS-CoV-2 coinfections in respiratory infections.3 Biotech · 2025Review
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
- Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge.NPJ vaccines · 2024Article
- Analysis of BeyfortusCurrent issues in molecular biology · 2024Review
- The Modification of the IlluminaInternational journal of molecular sciences · 2023Article
- Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia.The journal of allergy and clinical immunology. Global · 2023Article
- Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities.Infectious diseases and therapy · 2023Review
- A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability.Frontiers in immunology · 2023Article
- RSV disease in infants and young children: Can we see a brighter future?Human vaccines & immunotherapeutics · 2022Article
- Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.Biomedicines · 2022Review
- Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.Frontiers in immunology · 2022Article
- Avian Cell Line DuckCeltVaccines · 2021Article
- Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.Cell reports · 2021Article
- Epidemiology and prevention of respiratory syncytial virus infections in children in Italy.Italian journal of pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) represents the main cause of acute respiratory tract infections in children worldwide and is the leading cause of hospitalization in infants. RSV infection is a self-limiting condition and does not require antibiotics. However hospitalized infants with clinical bronchiolitis often receive antibiotics for fear of bacteria coinfection, especially when chest radiography is performed due to similar radiographic appearance of infiltrate and atelectasis. This may lead to unnecessary antibiotic prescription, additional cost, and increased risk of development of resistance. Despite the considerable burden of RSV bronchiolitis, to date, only symptomatic treatment is available, and there are no commercially available vaccines. The only licensed passive immunoprophylaxis is palivizumab. The high cost of this monoclonal antibody (mAb) has led to limiting its prescription only for high-risk children: infants with chronic lung disease, congenital heart disease, neuromuscular disorders, immunodeficiencies, and extreme preterm birth. Nevertheless, it has been shown that the majority of hospitalized RSV-infected children do not fully meet the criteria for immune prophylaxis. While waiting for an effective vaccine, passive immune prophylaxis in children is mandatory. There are a growing number of RSV passive immunization candidates under development intended for RSV prevention in all infants. In this review, we describe the state-of-the-art of palivizumab's usage and summarize the clinical and preclinical trials regarding the development of mAbs with a better cost-effectiveness ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.